

# TNF Inhibitor Significantly Slowed RA Progression

BY HEIDI SPLETE

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

ROME — Tumor necrosis factor inhibitors significantly reduced joint damage progression in patients with rheumatoid arthritis after 2 years, compared with conventional treatment, based on data from a nationwide observational cohort study.

The progression rate during anti-TNF treatment was reduced by 61%, compared with usual treatment with disease-modifying antirheumatic drugs, said Dr. Lykke Ørnberg of Copenhagen University Hospital in Hvidovre, Denmark.

Data from real-life studies of TNF inhibitors to prevent disease progression in RA patients are limited, the researchers noted. They reviewed data from 522 RA patients with an average age of 54 years and average disease duration of 5 years. Most (76%) of the patients were women, 80% were rheumatoid factor positive, 65% were anti-cyclic citrullinated peptide antibody positive, and 27% were smokers.

Conventional radiographs were taken of the patients' hands and wrists at three time points: approximately 2 years before starting TNF inhibitors (time point A), at about the start of TNF inhibitor therapy (time point B), and approximately 2 years after the start of treatment with a TNF inhibitor (time point C).

On three measurements of disease progression (total van der Heijde–Sharp scores, erosion, and joint-space narrowing), the difference in progression was significantly higher between time points A and B (treatment with DMARDs), compared with time points B and C (treatment with a TNF inhibitor). The mean total van der Heijde–Sharp scores between time points A and B vs. B and C were 2.1 vs. 0.67, respectively. The mean erosion scores were 1.04 vs. 0.36, respectively, and the mean joint-space narrowing scores were 1 vs. 0.31, respectively.

The percentage of patients who showed progression of RA was 59% between time points A and B, compared with 31% between time points B and C. The mean value on the 28-joint disease activity score (DAS28) was 4.4 at time point A, 5.0 at time point B, and 3.1 at time point C.

At time point A, 45% of the patients received methotrexate, 22% sulphasalazine, 12% hydroxychloroquine, and 5% leflunomide. Another 6% received other treatments, and 10% received no DMARDs. At time point B, 61% of the patients received infliximab, 24% received adalimumab, and 15% received etanercept. The patients were selected from DANBIO, an ongoing nationwide registry of rheumatology patients in Denmark.

The data show that “even in ‘real-life’ practice, . . . treatment with a [TNF inhibitor] halts radiographic progression in the majority of RA patients when they switch from DMARDs,” Dr. Ørnberg said. ■

**Disclosure:** Dr. Ørnberg reported that she had no financial conflicts of interest to disclose. She reported that Centocor Inc. sponsored the data analysis.

📺 To watch an interview of Dr. Ørnberg, go to [www.youtube.com/elsglobalmedicalnews](http://www.youtube.com/elsglobalmedicalnews) and click on “Playlists.” Then click on RHEUMATOLOGY NEWS.



Dr. Lykke Ørnberg said that the data showing TNF inhibitors slow progression are great news for clinicians who treat RA patients routinely.

HEIDI SPLETE/ELSEVIER GLOBAL MEDICAL NEWS

If your patients present with acute pain due to minor strains, sprains, or contusions...

**Prescribe the NSAID patch**

#### Indication

FLECTOR® Patch (diclofenac epolamine topical patch) 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Carefully consider the potential benefits and risks of FLECTOR® Patch and other treatment options before deciding to use FLECTOR® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

#### Important Safety Information

##### Cardiovascular (CV) risk

- FLECTOR® Patch, like other NSAIDs, may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk
- FLECTOR® Patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery

##### Gastrointestinal (GI) risk

- NSAIDs, including FLECTOR® Patch, cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious GI events

FLECTOR® Patch is contraindicated in patients with known hypersensitivity to diclofenac. FLECTOR® Patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

FLECTOR® Patch should not be applied to nonintact or damaged skin resulting from any etiology, eg, exudative dermatitis, eczema, infected lesion, burns, or wounds.

NSAIDs, including FLECTOR® Patch, can lead to new onset or worsening of hypertension, contributing to increased incidence of CV events. Fluid retention and edema have been observed in some patients taking NSAIDs, including FLECTOR® Patch. Use with caution and monitor patients with hypertension, fluid retention, or heart failure.

Elevations of one or more liver tests may occur during therapy with FLECTOR® Patch. If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur, FLECTOR® Patch should be discontinued immediately.

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in maintaining renal perfusion. Use FLECTOR® Patch with caution in patients at greatest risk of this reaction, including the elderly, those with impaired renal function, heart failure, liver dysfunction, and those taking